[1] Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis [J]. Nat Rev Nephrol, 2017, 13(2):90-103.
[2] 徐天 .mTOR 通路在腹膜纤维化的作用及 PWV 对腹透患者 CVD 的预测价值[D].上海交通大学,2017.
[3] Zhou Q, Bajo MA, Del Peso G, et al. Preventing perito-neal membrane fibrosis in peritoneal dialysis patients [J]. Kidney Int, 2016，90(3):515-524.
[4] 童孟立. 腹膜透析患者腹膜纤维化发生机制及防治的研究进展[J].浙江医学,2020,42(06):529-532.
[5] Aroeira LS, Aguilera A, Sánchez-Tomero JA, et al. Epi-thelial to mesenchymal transition and peritoneal mem-brane failure in peritoneal dialysis patients: patho-logic significance and potential therapeutic interven-tions[J]. J Am Soc Nephrol, 2007,18(7):2004-2013.
[6] Wang S, Song R, Wang Z, et al. S100A8/A9 in Inflamma-tion[J]. Front Immunol, 2018, 9: 1298.
[7] Pruenster M, Vogl T, Roth J, et al. S100A8/A9: From ba-sic science to clinical application[J]. Pharmacol Ther, 2016, 167: 120-131.
[8] Vogl T, Ludwig S, Goebeler M, et al. MRP8 and MRP14 control microtubule reorganization during transendo-thelial migration of phagocytes[J]. Blood, 2004, 104 (13): 4260-4268.
[9] Shabani F, Farasat A, Mahdavi M, et al. Calprotectin (S100A8/S100A9): A key protein between inflammation and cancer[J]. Inflamm Res, 2018, 67(10): 801-812.
[10] Holzinger D, Nippe N, Vogl T, et al. Myeloid- related proteins 8 and 14 contribute to monosodium urate mono-hydrate crystal- induced inflammation in gout[J]. Ar-thritis Rheumatol, 2014, 66(5): 1327-1339.
[11] 陶李, 杜明, 王昱斌, 等. 钙卫蛋白作为类风湿性关节炎诊断标志物的研究 [J]. 中国免疫学杂志, 2019, 35(16): 2011-2015.
[12] Kalla R, Kennedy NA, Ventham NT, et al. Serum calpro-tectin: A novel diagnostic and prognostic marker in inflammatory bowel diseases[J]. Am J Gastroenterol, 2016, 111(12): 1796-1805.
[13] 毛佳燕. 血清钙卫蛋白水平在判断炎症性肠病活动程度中的意义[D]. 苏州：苏州大学, 2017.
[14] Hesselstrand R, Wildt M, Bozovic G, et al. Biomarkers from bronchoalveolar lavage fluid in systemic sclero-sis patients with interstitial lung disease relate to severity of lung fibrosis[J]. Respir Med, 2013, 107 (7): 1079-1086.
[15] 李艳菊. 2型糖尿病肾病患者血清钙卫蛋白(S100A8/A9)水平的相关性研究[D]. 银川：宁夏医科大学, 2020.
[16] Burkhardt K, Schwarz S, Pan C, et al. Myeloid- related protein 8/14 complex describes microcirculatory alter-ations in patients with type 2 diabetes and nephropa-thy[J]. Cardiovasc Diabetol, 2009, 8: 10.
[17] Wu Y, Li Y, Zhang C, et al. S100a8/a9 released by CD11b Gr1 neutrophils activates cardiac fibroblasts to initiate angiotensin II- Induced cardiac inflamma-tion and injury[J].Hypertension,2014,63(6):1241-1250.
[18] Magi B, Bini L, Perari MG, et al. Bronchoalveolar la-vage fluid protein composition in patients with sar-coidosis and idiopathic pulmonary fibrosis: a two- di-mensional electrophoretic study[J]. Electrophoresis, 2002, 23(19):3434-3444.
[19] 孙巧敏, 张晓霞. 特发性肺纤维化患者血清淀粉样蛋白 A 和钙卫蛋白水平变化及临床意义研究 [J]. 检验医学与临床, 2021, 18(14): 2061-2064.
[20] Tanaka K, Enomoto N, Hozumi H, et al. S Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerba-tion of idiopathic pulmonary fibrosis[J]. Respir In-vestig, 2021, 59(6): 827-836.
[21] Tammaro A, Florquin S, Brok M, et al. S100A8/A9 pro-motes parenchymal damage and renal fibrosis in ob-structive nephropathy[J]. Clin Exp Immunol, 2018, 193 (3): 361-375.
[22] Zhong A, Xu W, Zhao J, et al. S100A8 and S100A9 Are induced by decreased hydration in the epidermis and promote fibroblast activation and fibrosis in the der-mis[J]. Am J Pathol, 2016, 186(1): 109-122.
[23] Zhu L, Chen D, Zhu Y, et al. GPX4- Regulated ferropto-sis mediates s100-induced experimental autoimmune hep-atitis associated with the Nrf2/HO-1 signaling pathway [J]. Oxid Med Cell Longev, 2021, 2021: 6551069.
[24] Lovisa S, Zeisberg M, Kalluri R. Partial epithelial-to-mesenchymal transition and other new mechanisms of kidney fibrosis[J]. Trends Endocrinol Metab, 2016, 27 (10): 681-695.
[25] Bj?rk P, Bj?rk A, Vogl T, et al. Identification of hu-man S100A9 as a novel target for treatment of autoim-mune disease via binding to quinoline- 3- carboxamides [J]. PLoS Biol, 2009, 7(4): e97.
[26] Schelbergen RF, Geven EJ, van den Bosch MH, et al. Prophylactic treatment with S100A9 inhibitor paquini-mod reduces pathology in experimental collagenase- in-duced osteoarthritis[J]. Ann Rheum Dis, 2015, 74(12): 2254-2258.
[27] Bengtsson AA, Sturfelt G, Lood C, et al. Pharmacokinet-ics, tolerability, and preliminary efficacy of paquin-imod (ABR- 215757), a new quinoline- 3- carboxamide de-rivative: studies in lupus- prone mice and a multi-center, randomized, double- blind, placebo- controlled, repeat- dose, dose- ranging study in patients with sys-temic lupus erythematosus[J]. Arthritis Rheum, 2012, 64(5): 1579-1588.
[28] He D, Han K, Gao X, et al. Laquinimod for multiple sclerosis[J]. Cochrane Database Syst Rev, 2013, (8): CD010475.
[29] Araki K, Kinoshita R, Tomonobu N, et al. The heterodi-mer S100A8/A9 is a potent therapeutic target for idio-pathic pulmonary fibrosis[J]. J Mol Med (Berl), 2021, 99(1): 131-145.
